Chelation therapy to prevent heart attacks has never been accepted by mainstream cardiologists, but it is popular none the less, and increasingly so in the wake of trials questioning the value of drug-eluting stents. The Trial to Assess Chelation Therapy (TACT), a $30 million NIH-sponsored study, will hopefully provide definitive answers on whether chelation has a rightful place in heart disease prevention.